Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

Clinuvel Pharmaceuticals (ASX:CUV) Shares Rise as Clinical Pipeline Gains Investor Focus

Clinuvel Pharmaceuticals (ASX:CUV) shares closed at AUD 10.89, up 4.71% on 20 August 2026. The movement reflects a positiveTrading sessionas investors continue to assess the company’s commercial pharmaceutical platform, clinical pipeline and expansion initiatives.

Aditi Sarkar | 20 August 2026

Cogstate (ASX:CGS): Record Sales Pipeline, Favourable Margins and Global Expansion in Focus

Cogstate Limited (ASX:CGS) shares closed at AUD 3.08, up 5.12% on 20 August 2026. The movement reflects a strongerTrading sessionas investors continue to assess the company’s neuroscience technology platform, clinical trialDemandand expanding contracted revenue base.

Aditi Sarkar | 20 August 2026

Australian Clinical Labs (ASX:ACL) Gains as Investors Assess Margin Improvement Strategy

Australian Clinical Labs Limited (ASX:ACL) shares closed at AUD 2.89, up 1.40% on 20 August 2026. The movement reflects a positiveTrading sessionas investors continue to assess the company’s pathology services platform, operational efficiency initiatives and outlook following its FY26 performance update.

Aditi Sarkar | 20 August 2026

Why Nanosonics’ (ASX:NAN) Recurring Revenue Model Is Becoming Central to Its Healthcare Strategy?

Nanosonics Limited (ASX:NAN) shares closed at AUD 3.60, down 1.10% on 20 August 2026. The movement reflects a weakerTrading sessionas investors continue to assess the company’s infection prevention technology platform, product expansion strategy and healthcare market opportunities.

Aditi Sarkar | 20 August 2026

Clarity Pharmaceuticals (ASX:CU6) Gains Attention as Clinical Milestones and Manufacturing Plans Progress

Clarity Pharmaceuticals Limited (ASX:CU6) shares closed at AUD 2.62, up 5.22% on 20 August 2026. The movement reflects a positiveTrading sessionas investors continue to assess the company’s radiopharmaceutical pipeline, clinical development programs and preparation for potential commercialisation.

Aditi Sarkar | 20 August 2026

Integral Diagnostics (ASX:IDX): Capitol Health Integration and Margin Growth Remain Key Investor Themes

Integral Diagnostics Limited (ASX:IDX) shares closed at AUD 2.28, up 1.79% on 20 August 2026. The movement reflects a positiveTrading sessionas investors continue to assess the company’s diagnostic imaging platform,Acquisitionintegration progress and healthcare services growth strategy.

Aditi Sarkar | 20 August 2026

Artrya (ASX:AYA) Surges as Investors Track US Customer Growth and Regulatory Milestones

Artrya Limited (ASX:AYA) shares closed at AUD 5.05, up 8.60% on 20 August 2026. The movement reflects a strongerTrading sessionas investors continue to assess the company’s artificial intelligence (AI)-powered cardiac imaging platform, US healthcare expansion and commercialisation progress.

Aditi Sarkar | 20 August 2026

Imricor Medical Systems (ASX:IMR): FDA Progress and US Hospital Adoption Remain Key Focus Areas

Imricor Medical Systems (ASX:IMR) shares closed at AUD 2.05, down 0.49% on 20 August 2026. The movement reflects a slightly weakerTrading sessionas investors continue to assess the company’s MRI-guided cardiac technology platform, US commercial expansion and regulatory progress.

Aditi Sarkar | 20 August 2026

Polynovo (ASX:PNV) Under Spotlights as Investors Assess Record Revenue and Cash Flow Progress

Polynovo Limited (ASX:PNV) shares closed at AUD 1.11, up 6.73% on 20 August 2026. The movement reflects a strongerTrading sessionas investors continue to assess the company’s advanced wound care technology platform, global sales growth and commercial expansion strategy.

Aditi Sarkar | 20 August 2026

From Respiratory Imaging to AI Diagnostics: How 4DMedical (ASX:4DX) Is Building a Global Healthcare Platform?

4DMedical Limited (ASX:4DX) shares closed at AUD 4.02, up 6.07% on 20 August 2026. The movement reflects a positiveTrading sessionas investors continue to assess the company’s respiratory imaging technology platform, commercial rollout progress and global expansion strategy.

Aditi Sarkar | 20 August 2026
Support

Hi! How can we help you today?

Loading…